drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Anti-HER2 IgG1 antibody–drug conjugate that targets HER2-expressing tumor cells and delivers MMAE; internalization and linker cleavage release MMAE to inhibit tubulin polymerization, causing G2/M arrest and apoptosis; may also trigger ADCC and a bystander effect.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Disitamab Vedotin
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Disitamab vedotin is an anti-HER2 IgG1 antibody–drug conjugate that binds HER2 on tumor cells, is internalized, and releases the payload MMAE via a cleavable linker. MMAE inhibits tubulin polymerization, causing G2/M cell-cycle arrest and apoptosis. The IgG1 backbone may also mediate ADCC, and released MMAE can produce a bystander killing effect.
drug_name
disitamab vedotin (RC48-ADC)
nct_id_drug_ref
NCT05943379